Brand Name : Erleada
Composition : Apalutamide
Strength availability : 60mg
Manufactured by : Janssen Biotech.Inc
Pack : 120 tablets
for MORE INFORMATION !!!
Apalutamide is a generic form of brand name Erleada 60mg and it is a prescription medicine used under the guidance of medical practioners.
Erleada 60mg belongs to antiandrogen, and works as an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. In doing so, it inhibits the effects of these hormones in the prostate gland and elsewhere in the body.
It is unknown if Erleada 60mg is safe or persuasive in children.
Erleada 60mg is indicated for the treatment in patients having nonmetastatic castration-resistant prostate cancer (NM-CRPC)
Time to peak plasma concentration is 2hr and peak plasma concentration is 6mcg/mL and 5.9mcg/mL and steady-state achieved is 4 weeks
Human plasma protein binding of Apalutamide is 96% and N-desmethyl Apalutamide
Mainly the drug metabolized by CYP2C8 for the formation of N-desmethyl Apalutamide
Apalutamide excreted via urine 65% and feces 24%
Half-life is 3 days
Erleada recommended dose for adult is 240mg administrated four tablets containing 60mg given orally once daily.
The whole tablet should be swallow
Erleada tablet can be consume with or without food
Along with Apalutamide the patients should also receive a gonadotropin-releasing hormone(GnRH) associated concurrently or should have had a bilateral orchiectomy
While patients have ≥ grade 3 toxicity or intolerable adverse reaction then dosage modification should be required.
Wait dosing until symptoms improve to ≤Grade 1 or original grade, after that proceed at the same dose or a decreased dose (180 mg or 120 mg), if warranted.
Apalutamide (ZD-6474) is a potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (Rearranged during Transfection) tyrosine kinases. VEGFR- and EGFR-dependent indicating are both clinically certify pathways in cancer, containing non-small-cell lung cancer (NSCLC).
Falls and Fractures:
While using Erleada 60mg tablets will causes falls and fractures, patients should evaluate for risk and monitor and manage patients at risk for fractures along with established treatment guidelines.
Erleada 60mg may causes seizures then permanently discontinue if seizure occurs during treatment. Hence advise patients about developing risk due to seizure, it may lead to sudden loss of memory while engaging in activities.
Erleada interaction with strong CYP2C8 or CYP3A4 inhibitor is determined to have high the steady state exposure of the active molecule. Erleada co administration with primarily metabolized by CYP3A4, CYP2C19 or CYP2C9 can reported in reduce exposure to these medications
Erleada is contraindicated in pregnant women because it will cause risk to fetal and probably loss of pregnancy
If dose is missed, then take the dose immediately before reach of next dose time or skip the missed dose and continue the regular schedule. Do not have extra dose which leads to over dosage Consult the doctor about missed dose and overdose
Store the drug at 20℃ to 25℃. Store in the original container. Protect from light and moisture.
Erleada has caused some side effect but most people will not affect all the side effect listed :
The drugs Common side effects which occurring in greater than 30% are:
Fatigue, Decreased blood count, Cholesterol and triglycerides increased, Blood sugar level increased, Potassium levels increased, Less common side effects occurring in 10-29%, Nausea, Peripheral edema, Hot flashes, Skin rash, Dizziness/falling, Thyroid dysfunction, Muscle weakness, Increased blood pressure, Diarrhea, Joint pain, Lack of appetite, Falls, Fractures, Weight loss.